Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

People walk past a Walgreens storefront in San Francisco, Calif., in a file photo.

Ben Margot/The Associated Press

Walgreens Boots Alliance Inc said on Thursday it would take majority stakes in two smaller health care providers for about $5.5-billion, as the second largest U.S. pharmacy chain shifts focus beyond its drugstores.

Shares in Walgreens rose nearly 7 per cent to $50.44 in afternoon trading after it reported fourth-quarter results that beat estimates, helped by easing pandemic-related restrictions and COVID-19 vaccine administrations at its stores.

The company said it would make a $5.2-billion investment in VillageMD, raising its stake in the primary care provider to 63 per cent. It will also invest $330-million in post-acute and home care provider CareCentrix to take a 55 per cent stake.

Story continues below advertisement

Walgreens, which has more than 9,000 drugstores across the country, said these investments will support its new business unit that will provide pharmacy and primary care services in-store, at home, in the doctor’s office and via mobile app.

Rosalind Brewer, who took over as CEO earlier this year, said the deals will help Walgreens manage rising costs in high-risk patients. “These are the same patients who frequently visit our stores and meet with our pharmacists,” Brewer added.

Walgreens said it expects adjusted earnings growth, at constant currency rates, to be flat for fiscal year 2022.

The company aims to open at least 600 physician-led primary care clinics in more than 30 U.S. markets by 2025 and 1,000 clinics by 2027.

Walgreens and VillageMD have 52 primary care practice locations with pharmacy and doctor offices together, and will have more than 80 such locations by the end of this calendar year, the company said.

Same-store sales at its U.S. pharmacies rose 8.8 per cent in the fourth quarter, which included a 485 basis point boost from COVID-19 vaccinations, the company said.

Excluding items, Walgreens earned $1.17 per share, compared with Refinitiv IBES estimates of $1.02 per share.

Story continues below advertisement

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies